Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2018
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Open access · bronzeAbstract readClinical Trial, Phase III
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Predicting Immunotherapy Efficacy with Machine Learning in Gastrointestinal Cancers: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Biologically-informed integration of drug representations for breast cancer treatment using deep learning.Nature communications · 2025Trial
- Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.Cell reports. Medicine · 2025Trial
- Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.British journal of cancer · 2023Trial
- Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).Nature communications · 2020Trial
- NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Artificial intelligence integrated multi-omics and multimodal studies promote the efficacy of neoadjuvant chemotherapy in breast cancer: opportunities, challenges, and future perspectives.Breast cancer research : BCR · 2026Review
- Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.bioRxiv : the preprint server for biology · 2025Article
- Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer.Science advances · 2025Article
- Analysis of methylation features associated with neoadjuvant efficacy in HER2-positive breast cancer.Frontiers in oncology · 2025Article
- In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pertuzumab.International journal of molecular sciences · 2024Article
- iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics data.BMC bioinformatics · 2024Article
- PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors.Nature cancer · 2024Article
- Gene-Expression Profiling to Decipher Breast Cancer Inter- and Intratumor Heterogeneity.Cold Spring Harbor perspectives in medicine · 2024Review
- Association of inflammatory blood markers and pathological complete response in HER2-positive breast cancer: a retrospective single-center cohort study.Frontiers in immunology · 2024Article
- Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer.JAMA network open · 2023Article
- iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics data.Research square · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 1 country.
Maki TaniokaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Cheng FanLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-1216-477X
Zhiyuan HuLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-2963-2453
Yan LiLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Terry M HyslopAlliance Statistics and Data Center, Duke University, Durham, North Carolina.
Brandelyn N PitcherAlliance Statistics and Data Center, Duke University, Durham, North Carolina.
Matthew G SolowayLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Patricia A SpearsLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Lynn N HenryUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0002-4771-5930
Sara TolaneyDana Farber Cancer Institute, Boston, Massachusetts.
Chau T DangMemorial Sloan Kettering Cancer Center, New York, New York.
Ian E KropDana Farber Cancer Institute, Boston, Massachusetts.
Lyndsay N HarrisNational Cancer Institute, Bethesda, Maryland.
Donald A BerryAlliance Statistics and Data Center, M.D. Anderson, Houston, Texas.
Elaine R MardisThe Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Eric P WinerDana Farber Cancer Institute, Boston, Massachusetts.
Clifford A HudisMemorial Sloan Kettering Cancer Center, New York, New York.
Lisa A CareyLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. cperou@med.unc.edu.
University of North Carolina at Chapel Hill · USDana-Farber Cancer Institute · USDuke University · USKettering University · USNational Cancer Institute · USNationwide Children's Hospital · USThe University of Texas MD Anderson Cancer Center · USUniversity of Utah · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MMember Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MTissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHARLES M PEROU · 1992 to 2026
$59.3MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3MCenter for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4MUT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1UG1CA233329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KELLY K HUNT, CHELSEA Camille PINNIX · 2019 to 2026
$11.1MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2MUT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)U10CA180858 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUNT, KELLY K, PINNIX, CHELSEA CAMILLE · 2014 to 2018
$5.6MHuntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site ApplicationUG1CA233178 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Matthew Poppe, Heloisa Prado Soares · 2019 to 2026
$4.9MUM LAPs- U10 GrantU10CA180801 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZALUPSKI, MARK M · 2014 to 2018
$3.7MNCATS NIH HHS UL1 TR000371NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA058223NCI NIH HHS R01 CA195740NCI NIH HHS U10 CA180801NCI NIH HHS U10 CA180818NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180838NCI NIH HHS U10 CA180858NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS U10 CA181009NCI NIH HHS UG1 CA233178NCI NIH HHS UG1 CA233329NIEHS NIH HHS P30 ES010126
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsComputational BiologyDNA Copy Number VariationsDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleGene Expression ProfilingGenomicsHumansMutationNeoadjuvant TherapyPrognosisTranscriptomeTrastuzumabBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesTrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.